Drugs / Tcrx T cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05447234 | Mar 2023 → Mar 2026 overdue | gastric cancer, gastroesophageal cancer | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tcrx T cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05447234 ↗ |
| Modality | Cell therapy | “gene-edited T cells” NCT05447234 ↗ |
| Route | Intravenous | “Sequential IV infusion” NCT05447234 ↗ |